These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 15116251

  • 1. The anticoagulant action of recombinant human activated protein C (rhAPC, Drotrecogin alpha activated): comparison between cord and adult plasma.
    Cvirn G, Gallistl S, Koestenberger M, Baier K, Fritsch P, Greilberger J, Jürgens G, Muntean W.
    Thromb Haemost; 2004 May; 91(5):912-8. PubMed ID: 15116251
    [Abstract] [Full Text] [Related]

  • 2. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
    Koestenberger M, Gallistl S, Muntean W, Leschnik B, Fritsch P, Cvirn G.
    Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
    [Abstract] [Full Text] [Related]

  • 3. Protein S modulates the anticoagulant action of recombinant human activated protein C: a comparison between neonates and adults.
    Cvirn G, Koestenberger M, Leschnik B, Male C, Kutschera J, Ferstl U, Muntean W, Juergens G, Gallistl S.
    Br J Pharmacol; 2005 Dec; 146(8):1082-6. PubMed ID: 16273121
    [Abstract] [Full Text] [Related]

  • 4. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
    Koestenberger M, Cvirn G, Gallistl S, Muntean W.
    Blood Coagul Fibrinolysis; 2004 Oct; 15(8):693-7. PubMed ID: 15613925
    [Abstract] [Full Text] [Related]

  • 5. Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma.
    Koestenberger M, Cvirn G, Gallistl S, Kutschera J, Muntean W.
    Acta Paediatr; 2005 Jul; 94(7):884-9. PubMed ID: 16188810
    [Abstract] [Full Text] [Related]

  • 6. Drotrecogin alfa (activated, Xigris) in combination with heparin or melagatran: an in vitro investigation.
    Koestenberger M, Cvirn G, Gallistl S, Baier K, Leschnik B, Muntean W.
    J Thromb Thrombolysis; 2004 Aug; 18(1):5-10. PubMed ID: 15744547
    [Abstract] [Full Text] [Related]

  • 7. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
    Koestenberger M, Gallistl S, Cvirn G, Baier K, Leschnik B, Muntean W.
    Thromb Res; 2005 Aug; 115(1-2):135-42. PubMed ID: 15567465
    [Abstract] [Full Text] [Related]

  • 8. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.
    Baier K, Cvirn G, Fritsch P, Köstenberger M, Gallistl S, Leschnik B, Muntean W.
    Pediatr Res; 2005 May; 57(5 Pt 1):685-9. PubMed ID: 15718352
    [Abstract] [Full Text] [Related]

  • 9. Elevated thrombin-forming capacity of tissue factor-activated cord compared with adult plasma.
    Cvirn G, Gallistl S, Rehak T, Jürgens G, Muntean W.
    J Thromb Haemost; 2003 Aug; 1(8):1785-90. PubMed ID: 12911594
    [Abstract] [Full Text] [Related]

  • 10. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
    Cimenti C, Koestenberger M, Leschnik B, Haidl H, Muntean W.
    Thromb Res; 2007 Aug; 119(3):361-7. PubMed ID: 16712904
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response.
    Robriquet L, Collet F, Tournoys A, Prangère T, Nevière R, Fourrier F, Guery BP.
    Respir Res; 2006 Mar 22; 7(1):41. PubMed ID: 16553944
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of recombinant activated protein C and low-dose heparin on neutrophil-endothelial cell interactions in septic shock.
    Kirschenbaum LA, Lopez WC, Ohrum P, Tsen A, Khazin J, Astiz ME.
    Crit Care Med; 2006 Aug 22; 34(8):2207-12. PubMed ID: 16775572
    [Abstract] [Full Text] [Related]

  • 20. The impact of tissue factor pathway inhibitor on coagulation kinetics determined by thrombelastography.
    Audu P, Nielsen VG, Armstead V, Powell G, Kim J, Kim L, Mehta M.
    Anesth Analg; 2006 Oct 22; 103(4):841-5. PubMed ID: 17000790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.